SLC31A2

Summary

SLC31A2 (solute carrier family 31 member 2, HGNC:11017) is a protein-coding gene on chromosome 9q32, encoding Protein SLC31A2 (O15432). Does not function as a copper(1+) importer in vivo.

Enables copper ion transmembrane transporter activity. Involved in copper ion import. Located in late endosome membrane; lysosomal membrane; and plasma membrane.

Source: NCBI Gene 1318 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 9 total
• Druggable target: yes
• MANE Select transcript: NM_001860

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11017
Approved symbol	SLC31A2
Name	solute carrier family 31 member 2
Location	9q32
Locus type	gene with protein product
Status	Approved
Aliases	hCTR2, CTR2
Ensembl gene	ENSG00000136867
Ensembl biotype	protein_coding
OMIM	603088
Entrez	1318

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 1 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000259392, ENST00000374220, ENST00000490809

RefSeq mRNA: 1 — MANE Select: NM_001860 NM_001860

CCDS: CCDS6788

Canonical transcript exons

ENST00000259392 — 4 exons

Exon	Start	End
ENSE00001666797	113157727	113157793
ENSE00001856316	113151007	113151080
ENSE00003474818	113162749	113164140
ENSE00003613561	113161509	113161698

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 98.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.2764 / max 546.2144, expressed in 1714 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
98068	14.3990	1411
98067	5.0204	1534
98069	0.8571	376

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	98.85	gold quality
inferior vagus X ganglion	UBERON:0005363	98.35	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.51	gold quality
spinal cord	UBERON:0002240	97.11	gold quality
corpus callosum	UBERON:0002336	96.10	gold quality
pons	UBERON:0000988	95.95	gold quality
subthalamic nucleus	UBERON:0001906	95.48	gold quality
medulla oblongata	UBERON:0001896	95.16	gold quality
monocyte	CL:0000576	94.97	gold quality
mononuclear cell	CL:0000842	94.84	gold quality
superior vestibular nucleus	UBERON:0007227	94.82	gold quality
decidua	UBERON:0002450	94.74	gold quality
leukocyte	CL:0000738	94.65	gold quality
ventral tegmental area	UBERON:0002691	94.58	gold quality
seminal vesicle	UBERON:0000998	94.48	gold quality
saliva-secreting gland	UBERON:0001044	94.45	gold quality
blood	UBERON:0000178	93.69	gold quality
inferior olivary complex	UBERON:0002127	93.26	gold quality
minor salivary gland	UBERON:0001830	93.19	gold quality
dorsal plus ventral thalamus	UBERON:0001897	93.05	gold quality
midbrain	UBERON:0001891	92.97	gold quality
skin of leg	UBERON:0001511	92.93	gold quality
upper leg skin	UBERON:0004262	92.91	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.83	gold quality
substantia nigra	UBERON:0002038	92.74	gold quality
skin of abdomen	UBERON:0001416	92.68	gold quality
zone of skin	UBERON:0000014	92.56	gold quality
mouth mucosa	UBERON:0003729	92.23	gold quality
upper arm skin	UBERON:0004263	91.93	gold quality
hair follicle	UBERON:0002073	91.42	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	24.96
E-ANND-3	yes	15.78
E-MTAB-5061	no	3.47

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

104 targeting SLC31A2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-17-5P	99.89	73.83	2665

Literature-anchored findings (GeneRIF, showing 10)

• hCTR2 is as an oligomeric membrane protein localized in lysosomes, which stimulates copper delivery to the cytosol of human cells at relatively high copper concentrations. (PMID:17617060)
• Ctr2 promotes copper uptake at the plasma membrane and plays a role in regulating copper levels in COS-7 cells (PMID:17944601)
• CTR2 functions by limiting drug accumulation, and its expression correlates with the sensitivity of human ovarian carcinoma cell lines to cisplatin. (PMID:19509135)
• Increased CTR2 expression is associated with platinum resistance in epithelial ovarian cancer. (PMID:23564780)
• Over-expression of CTR2 increased exchangeable Cu(+) by 150% and rendered the human epithelial 2008 cancer cell model 2.5-fold resistant to cisplatin. (PMID:24522273)
• Data suggest that SLC31A1 and SLC31A2, despite being structurally closely related and sharing important amino acid motifs, play different roles in copper homeostasis and in platinum-based chemotherapy of neoplasms. [REVIEW] (PMID:24703712)
• Studied the interaction of CTR1 and CTR2 in fully malignant HEK293T and OVCAR8 human ovarian cancer cells using a CRISPR-Cas9 knock out system. (PMID:26205368)
• Decreased expression of CTR2 is associated with clear cell renal cell carcinoma. (PMID:26411550)
• Gene duplication and neo-functionalization in the evolutionary and functional divergence of the metazoan copper transporters Ctr1 and Ctr2 (PMID:28507097)
• 11 single-nucleotide polymorphisms (SNPs) in CTR1, CTR2, ATP7A, and ATP7B were genotyped in these patients. (PMID:28737129)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc31a2	ENSDARG00000076092
mus_musculus	Slc31a2	ENSMUSG00000066152
rattus_norvegicus	Slc31a2	ENSRNOG00000013631
drosophila_melanogaster	Ctr1C	FBGN0062411
drosophila_melanogaster	Ctr1B	FBGN0062412
drosophila_melanogaster	Ctr1A	FBGN0062413
caenorhabditis_elegans		WBGENE00010274
caenorhabditis_elegans	F27C1.2	WBGENE00017852
caenorhabditis_elegans	K12C11.3	WBGENE00019674
caenorhabditis_elegans		WBGENE00044107
caenorhabditis_elegans	K12C11.6	WBGENE00045052

Paralogs (1): SLC31A1 (ENSG00000136868)

Protein

Protein identifiers

Protein SLC31A2 — O15432 (reviewed: O15432)

Alternative names: Copper transporter 2, Solute carrier family 31 member 2

All UniProt accessions (3): O15432, F2Z3D2, Q53X94

UniProt curated annotations — full annotation on UniProt →

Function. Does not function as a copper(1+) importer in vivo. However, in vitro functions as a low-affinity copper(1+) importer. Regulator of SLC31A1 which facilitates the cleavage of the SLC31A1 ecto-domain or which stabilizes the truncated form of SLC31A1 (Truncated CTR1 form), thereby drives the SLC31A1 truncated form-dependent endosomal copper export and modulates the copper and cisplatin accumulation via SLC31A1.

Subunit / interactions. Oligomer. Interacts with SLC31A1; this interaction stabilizes SLC31A2 and protects it from ubiquitination and the subsequent degradation.

Subcellular location. Membrane. Cytoplasmic vesicle membrane. Late endosome membrane. Lysosome membrane.

Tissue specificity. Ubiquitous with high expression in placenta and heart.

Post-translational modifications. Ubiquitinated; ubiquitination and the subsequent proteasomal degradation are prevent by SLC31A1 that stabilizes it.

Domain organisation. The N-terminal domain may be involved in Cu(2+) acquisition from potential degradation products of proteins in the lysosome.

Similarity. Belongs to the copper transporter (Ctr) (TC 1.A.56) family. SLC31A subfamily.

RefSeq proteins (1): NP_001851* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007274	Cop_transporter	Family

Pfam: PF04145

UniProt features (11 total): topological domain 4, transmembrane region 3, mutagenesis site 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15432-F1	71.98	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 77

Mutagenesis-validated functional residues (2):

Position	Phenotype
4	decreases almost 7 times the cu(2+) affinity at ph 7.4 compared to wild-type. decreases almost 10 times the cu(2+) affin
1–3	slightly decreases cu(2+) affinity at ph 7.4. decreases about 3 times the cu(2+) affinity at ph 7.4 compared to wild-typ

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 292 (showing top): RRAGTTGT_UNKNOWN, GOCC_VACUOLAR_MEMBRANE, GOBP_TRANSITION_METAL_ION_TRANSPORT, MODULE_45, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, KYNG_DNA_DAMAGE_DN, RACCACAR_AML_Q6, TGACCTY_ERR1_Q2, RIZKI_TUMOR_INVASIVENESS_3D_DN, USF_C, GOBP_COPPER_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN

GO Biological Process (6): copper ion transport (GO:0006825), intracellular copper ion homeostasis (GO:0006878), copper ion import (GO:0015677), regulation of copper ion transmembrane transport (GO:1902311), monoatomic ion transport (GO:0006811), copper ion transmembrane transport (GO:0035434)

GO Molecular Function (2): copper ion transmembrane transporter activity (GO:0005375), protein binding (GO:0005515)

GO Cellular Component (10): lysosomal membrane (GO:0005765), plasma membrane (GO:0005886), late endosome membrane (GO:0031902), recycling endosome (GO:0055037), lysosome (GO:0005764), endosome (GO:0005768), late endosome (GO:0005770), membrane (GO:0016020), cytoplasmic vesicle membrane (GO:0030659), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
copper ion transport	2
copper ion transmembrane transport	2
endosome	2
cytoplasmic vesicle	2
transition metal ion transport	1
intracellular monoatomic cation homeostasis	1
copper ion homeostasis	1
regulation of metal ion transport	1
regulation of monoatomic cation transmembrane transport	1
transport	1
monoatomic cation transmembrane transport	1
transition metal ion transmembrane transporter activity	1
binding	1
lysosome	1
lytic vacuole membrane	1
membrane	1
cell periphery	1
late endosome	1
endosome membrane	1
lytic vacuole	1
endomembrane system	1
cellular anatomical structure	1
vesicle membrane	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

1352 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC31A2	ATP7B	P35670	926
SLC31A2	ATP7A	Q04656	905
SLC31A2	ATOX1	O00244	810
SLC31A2	COX17	Q14061	756
SLC31A2	CCS	O14618	714
SLC31A2	COX11	Q9Y6N1	582
SLC31A2	SCO1	O75880	507
SLC31A2	SOD1	P00441	504
SLC31A2	SLC11A1	P49279	500
SLC31A2	IER3IP1	Q9Y5U9	500
SLC31A2	SLC11A2	P49281	498
SLC31A2	ERG28	Q9UKR5	492
SLC31A2	H3BSS0	H3BSS0	481
SLC31A2	CP	P00450	478
SLC31A2	ZFP37	Q9Y6Q3	478

IntAct

12 interactions, top by confidence:

A	B	Type	Score
SLC31A2	BNIP3	psi-mi:“MI:0915”(physical association)	0.560
GLP1R	SLC31A2	psi-mi:“MI:0915”(physical association)	0.510
SLC31A2	GLP1R	psi-mi:“MI:0915”(physical association)	0.510
SLC31A2	F2RL1	psi-mi:“MI:0915”(physical association)	0.370
SLC31A2	GPR35	psi-mi:“MI:0915”(physical association)	0.370
SLC31A2	HTR2B	psi-mi:“MI:0915”(physical association)	0.370
SLC31A2	OPRL1	psi-mi:“MI:0915”(physical association)	0.370
SLC31A2	PLSCR1	psi-mi:“MI:0914”(association)	0.350
SLC31A2	SLC31A1	psi-mi:“MI:0914”(association)	0.350
BNIP3	SLC31A2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): RAMP1 (Reconstituted Complex), RAMP2 (Reconstituted Complex), RAMP3 (Reconstituted Complex), SLC31A2 (Synthetic Lethality), BNIP3 (Two-hybrid), SLC31A2 (Two-hybrid), SLC31A2 (Two-hybrid), SLC31A2 (Two-hybrid), SLC31A2 (Two-hybrid), SLC6A8 (Affinity Capture-MS), PLSCR1 (Affinity Capture-MS), SLC9A6 (Affinity Capture-MS), AGPAT3 (Affinity Capture-MS), SLC20A2 (Affinity Capture-MS), CAV1 (Affinity Capture-MS)

ESM2 similar proteins: A0A142I735, A5DRE8, A8N1Z1, A9UY97, B0CQN9, B5XB24, F4JRE0, G4YM00, G4Z2L3, H1AE12, J9VLN4, J9VWN8, J9VX37, O13356, O15432, O94722, P0CS25, P30599, P38865, Q06686, Q12116, Q27783, Q2H0X9, Q39065, Q3T0K8, Q4W9R7, Q4WCY0, Q4WHY8, Q4WX45, Q4WYN3, Q52CS0, Q54LC9, Q59NP1, Q5J8M3, Q5RC35, Q61086, Q6GR43, Q6P011, Q6P6G5, Q6PBF7

Diamond homologs: O15431, O15432, P38865, Q4WHY8, Q4WX45, Q5RAS6, Q8K211, Q8WNR0, Q9CPU9, Q9JK41, Q9STG2, Q7XTF8, Q10KT6, Q39065, Q5ZD08, Q60EN8, Q69P80, Q8GWP3, Q8SAA5, Q93VM8, Q94EE4, Q9FGU8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

9 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	5
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

824 predictions. Top by Δscore:

Variant	Effect	Δscore
9:113151077:GGCG:G	donor_gain	1.0000
9:113151078:GCG:G	donor_gain	1.0000
9:113151078:GCGG:G	donor_gain	1.0000
9:113151080:GGTA:G	donor_loss	1.0000
9:113151081:G:GG	donor_gain	1.0000
9:113151081:GTA:G	donor_loss	1.0000
9:113151082:T:G	donor_loss	1.0000
9:113151076:TGGCG:T	donor_gain	0.9900
9:113151077:GGCGG:G	donor_gain	0.9900
9:113151079:CG:C	donor_gain	0.9900
9:113151080:GG:G	donor_gain	0.9900
9:113161503:TGACA:T	acceptor_loss	0.9900
9:113161504:GACAG:G	acceptor_loss	0.9900
9:113161505:ACAGG:A	acceptor_loss	0.9900
9:113161506:CAGGC:C	acceptor_loss	0.9900
9:113161507:A:T	acceptor_loss	0.9900
9:113161508:GGC:G	acceptor_gain	0.9900
9:113161508:GGCAT:G	acceptor_gain	0.9900
9:113161662:GC:G	donor_gain	0.9900
9:113161700:T:C	donor_loss	0.9900
9:113161704:GGCA:G	donor_gain	0.9900
9:113161705:GCAG:G	donor_gain	0.9900
9:113162747:AGGT:A	acceptor_gain	0.9900
9:113162748:GGTG:G	acceptor_gain	0.9900
9:113151759:G:GT	donor_gain	0.9800
9:113161507:A:AG	acceptor_gain	0.9800
9:113161508:G:GG	acceptor_gain	0.9800
9:113161708:G:GG	donor_gain	0.9800
9:113162745:CTAG:C	acceptor_loss	0.9800
9:113162746:TAG:T	acceptor_loss	0.9800

AlphaMissense

923 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:113162830:G:A	M115I	0.993
9:113162830:G:C	M115I	0.993
9:113162830:G:T	M115I	0.993
9:113162839:C:A	N118K	0.990
9:113162839:C:G	N118K	0.990
9:113162818:G:A	M111I	0.989
9:113162818:G:C	M111I	0.989
9:113162818:G:T	M111I	0.989
9:113157763:T:C	F15L	0.988
9:113157765:T:A	F15L	0.988
9:113157765:T:G	F15L	0.988
9:113162855:G:C	G124R	0.988
9:113157772:T:A	W18R	0.984
9:113157772:T:C	W18R	0.984
9:113162867:G:C	G128R	0.984
9:113162868:G:A	G128D	0.984
9:113162880:G:A	G132D	0.982
9:113162838:A:T	N118I	0.981
9:113162856:G:A	G124D	0.980
9:113162843:T:A	W120R	0.978
9:113162843:T:C	W120R	0.978
9:113162879:G:C	G132R	0.977
9:113157733:T:C	F5L	0.975
9:113157735:C:A	F5L	0.975
9:113157735:C:G	F5L	0.975
9:113162804:G:C	G107R	0.975
9:113161557:A:T	E41V	0.974
9:113162837:A:T	N118Y	0.974
9:113161567:G:C	K44N	0.972
9:113161567:G:T	K44N	0.972

dbSNP variants (sampled 300 via entrez): RS1000118432 (9:113162019 G>C), RS1000317304 (9:113160294 T>C), RS1000372828 (9:113153740 T>C), RS1000462913 (9:113149277 G>A), RS1000974677 (9:113155067 T>G), RS1001137094 (9:113155296 A>C), RS1001185470 (9:113161047 A>G), RS1001591562 (9:113159065 T>C), RS1001622162 (9:113152173 G>A), RS1001638039 (9:113160694 TC>T), RS1001965519 (9:113158696 G>C), RS1002928533 (9:113159364 C>A,T), RS1003011469 (9:113151060 C>A,T), RS1003236818 (9:113157338 C>T), RS1003294738 (9:113150893 G>A,C,T)

Disease associations

OMIM: gene MIM:603088 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST90002385_392	High light scatter reticulocyte count	6.000000e-11
GCST90002386_435	High light scatter reticulocyte percentage of red cells	9.000000e-10
GCST90002390_397	Mean corpuscular hemoglobin	7.000000e-20
GCST90002392_544	Mean corpuscular volume	8.000000e-23
GCST90002396_414	Mean reticulocyte volume	5.000000e-32
GCST90002397_692	Mean spheric corpuscular volume	1.000000e-40
GCST90002398_158	Neutrophil count	1.000000e-13

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007986	reticulocyte count
EFO:0004527	mean corpuscular hemoglobin
EFO:0010701	mean reticulocyte volume
EFO:0004833	neutrophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724592 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC31 family of copper transporters

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	7
Cisplatin	increases response to substance, increases uptake, affects localization, decreases degradation, affects uptake (+5 more)	5
Copper	decreases abundance, decreases expression, increases response to substance, increases uptake, decreases reaction (+1 more)	3
Cyclosporine	decreases expression	3
Estradiol	increases reaction, decreases expression	2
Tretinoin	increases expression	2
Particulate Matter	decreases expression, increases abundance	2
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
zinc chloride	decreases expression, increases expression	1
sodium arsenite	increases abundance, increases expression	1
tetrathiomolybdate	decreases response to substance	1
bathocuproine sulfonate	affects localization, decreases abundance, decreases expression, increases response to substance, increases uptake	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	decreases expression	1
Calcitriol	increases expression, affects cotreatment	1
Carbamazepine	affects expression	1
Dexamethasone	decreases expression	1
Ethyl Methanesulfonate	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5723786	Binding	RLU of HCTR2 at 1.0 µM in the Aequorin PRESTO-Tango GPCRome screen	Data for DCP probe T-10430

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4LP	HCT116-SLC31A2-KO-c1	Cancer cell line	Male
CVCL_D4LQ	HCT116-SLC31A2-KO-c9	Cancer cell line	Male
CVCL_E0NV	Ubigene HeLa SLC31A2 KO	Cancer cell line	Female
CVCL_TM98	HAP1 SLC31A2 (-) 1	Cancer cell line	Male
CVCL_XT17	HAP1 SLC31A2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.